On Thursday, Precision BioSciences Inc.’s DTIL partner iECURE reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study.ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal-onset Ornithine Transcarbamylase (OTC) deficiency. It utilizes a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables the insertion of a functional copy of the OTC gene.Ornithine transcarbamylase deficiency is a rare genetic condition that ...

Precision BioSciences (DTIL) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $3 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -258.23%. A quarter ago, it was expected that this genome editing company would post a loss of $0.77 per share when it actually produced earnings of $3.46, delivering a surprise of 549.35%.Over the last four quarters, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38841 Precision BioSciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-4206017 (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.000005 per share DTIL The Nasdaq Capital Market FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Octo ...

Precision BioSciences (DTIL) shares ended the last trading session 6.1% higher at $8.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.8% loss over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Precision BioSciences’ clinical-stage pipeline. In late September, the company submitted clinical trial applications across multiple ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher." Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ...

Precision BioSciences (DTIL) closed the last trading session at $9.71, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39.61 indicates a 307.9% upside potential. The mean estimate comprises five short-term price targets with a standard deviation of $19.39. While the lowest estimate of $19 indicates a 95.7% increase from the current price level, the most optimistic ana ...

Precision BioSciences (DTIL) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of a loss of $0.77 per share. This compares to loss of $3 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 549.35%. A quarter ago, it was expected that this genome editing company would post a loss of $0.45 per share when it actually produced a loss of $0.35, delivering a surprise of 22.22%. Over the last four ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------|------------------------------------------| | | | | ...

Exhibit 99.1 Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple i ...